Third‐Generation Anti–Cyclic Citrullinated Peptide Antibodies Improve Prediction of Clinical Arthritis in Individuals at Risk of Rheumatoid Arthritis-Reference-Cited by-同舟云学术

Third‐Generation Anti–Cyclic Citrullinated Peptide Antibodies Improve Prediction of Clinical Arthritis in Individuals at Risk of Rheumatoid Arthritis

Published:2020-09-07 Issue:11 Volume:72 Page:1820-1828
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Di Matteo Andrea¹^ORCID,Mankia Kulveer²,Duquenne Laurence²,Mahler Michael³,Corscadden Diane²,Mbara Katie²,Garcia‐Montoya Leticia²,Nam Jacqueline L.²,Emery Paul²^ORCID

Affiliation:

1. University of Leeds NIHR Leeds Biomedical Research Centre Leeds Teaching Hospitals NHS Trust, Leeds, UK, and Polytechnic University of Marche Carlo Urbani Hospital Jesi Italy

2. University of Leeds NIHR Leeds Biomedical Research Centre Leeds Teaching Hospitals NHS Trust Leeds UK

3. Inova Diagnostics, Inc. San Diego California United States

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41402

Reference40 articles.

1. Rheumatoid arthritis

2. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

3. Systematic Review: Accuracy of Anti–Citrullinated Peptide Antibodies for Diagnosing Rheumatoid Arthritis